Appraisal of immunoglobulin free light chain as a marker of response - Wikidata - thesis-toulmin - TriplyDB

Appraisal of immunoglobulin free light chain as a marker of response

Appraisal of immunoglobulin free light chain as a marker of response

http://www.wikidata.org/entity/Q24624398

about

Amyloid formation in light chain amyloidosis Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.Composite patient reports: a laboratory informatics perspective and pilot project for personalized medicine and translational research Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.Splenic plasma cells can serve as a source of amyloidogenic light chains Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.Risk Stratification in Multiple Myeloma.Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.The spot urine protein/creatinine ratio is a simple, rapid and inexpensive method for monitoring patients with light-chain multiple myeloma Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Quantitative serum free light chain assay--analytical issues.Screening panels for monoclonal gammopathies: time to change Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).Utilisation of sFLC assays - how well do we comply with guidelines?Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.Guidelines on the diagnosis and investigation of AL amyloidosis.Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens

P2860

Q27022257-C23EB5FE-BF01-4DAB-AB2C-251C52CFABAA Q33429992-0AC0AE9C-93B8-4287-B556-96F2957394A4 Q34585178-7E04AE31-30BC-4559-949F-3506F7508821 Q34637209-02D4A1E4-35CA-4368-B9DD-8F9112FD40AE Q36137449-13A1136F-2BA8-46C6-862C-AD6047B27457 Q36525219-09CAA6A8-BF83-44C5-8237-E5AEEFF876F3 Q36570225-7AF62AA2-6A46-42AF-AF42-3EB7C785BC19 Q36572310-17122D59-AC75-4B52-B870-B9818FF946CA Q36675330-3B2155C6-B183-4668-93ED-7A36240196C3 Q37100733-59FFA4B8-75DE-4C40-A64E-9E10C50926BE Q37370051-21953FC4-2FC4-4473-93D0-37C5AEDF6B44 Q37411236-25958A83-C8E5-49D0-B496-AC21108C8891 Q37528072-3795D6C1-C20C-4B2C-9EE1-36375268B750 Q37821496-A48F3A28-2AD6-4BA8-811E-0C8443BCEDE4 Q38168869-86F4BC98-B80D-4485-B99D-C501B703B5E4 Q38249930-BEF38D08-2082-426A-AE5B-4F16A39EB7E5 Q38398899-5AFB9839-219E-40D4-92DA-19D959707C19 Q38736249-887BE154-CA87-4942-92DC-078F87E812D6 Q38831139-956A510B-730C-467D-9DBF-01EAAF61DBE8 Q38911216-18FBD583-BD21-4527-82EE-7B4401FB7260 Q39491956-042D450D-B598-4586-9358-849F24CB9DAD Q40075903-3CEE18CA-2972-4F1C-AD14-9C4860A59475 Q40332106-39E19316-BBB5-4C52-8D64-A4F4235527E6 Q40368431-F96BE5F2-8BE1-469F-B7F3-D6A698C80321 Q41994443-4B3F881D-62A1-49C8-A069-A07ECE7BE860 Q42098619-4F80C9E0-0675-4323-A746-1BFFC41821A8 Q42543905-3C890AB3-7583-4D59-A451-937A02F75043 Q43921722-5F9685E7-1594-4E8D-A77E-4EBCBFBD54D3 Q44558771-C5946445-2684-4B0B-BC7E-EA4EE542F908 Q44944338-A23395B5-720E-4FFE-822E-87A6B23E6ED9 Q47727308-A38144EC-9064-41F8-A2D6-20A1538E59B8 Q50898321-AD483767-1BE6-44E6-88FF-E16458CA78B3 Q53542897-35B296DE-A235-4FC8-BA47-4889D57B4EB0 Q55058605-9DDD2BBB-8D15-497F-9D2F-81A2C4BD8548 Q57903912-7E2E489F-E197-48EA-B220-FEE1F3957FCA

P2860

Appraisal of immunoglobulin free light chain as a marker of response

http://www.wikidata.org/entity/Q24624398

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Appraisal of immunoglobulin free light chain as a marker of response

@ast

Appraisal of immunoglobulin free light chain as a marker of response

@en

Appraisal of immunoglobulin free light chain as a marker of response

@nl

type

label

Appraisal of immunoglobulin free light chain as a marker of response

@ast

Appraisal of immunoglobulin free light chain as a marker of response

@en

Appraisal of immunoglobulin free light chain as a marker of response

@nl

prefLabel

Appraisal of immunoglobulin free light chain as a marker of response

@ast

Appraisal of immunoglobulin free light chain as a marker of response

@en

Appraisal of immunoglobulin free light chain as a marker of response

@nl

P1433

Q24624398-63D9069C-CCE3-4858-B445-884716488AD6

P1476

Q24624398-C789A53F-81C3-4759-9E8C-688B84715735

P2093

Q24624398-1C3CA39B-BE66-4EB0-A655-C1AF147FA6AB

Q24624398-22CBF147-BB1A-498E-9497-E1CDF15BD2F7

Q24624398-25688B84-E277-4364-B0EE-D8BFDC0CE6C4

Q24624398-35B5F0C9-3F81-46B7-8377-26B88194A3DE

Q24624398-70BAF664-6F6C-480A-9432-C1FBDC64985C

Q24624398-72179DFB-8949-434E-8137-D9228555CEB9

Q24624398-AC8BDE63-A054-42B6-AA74-852BEA9D2D66

Q24624398-B1D0BDD6-26F7-4042-A731-C94765F55BA3

Q24624398-D2A38FB7-A831-4866-9CC3-FD56EA9230B6

P2860

Q24624398-02CED9B5-17F6-4C6F-9C83-3AA1D62E7359

Q24624398-0B0A96A2-5D55-44BD-9341-5A690E482138

Q24624398-1D58CEB1-E3C9-4177-A1D0-EF194949C903

Q24624398-22C57746-A7A8-4C70-9BFC-7CFD26584ACA

Q24624398-24876C64-DD91-45AD-BBFF-510823C7EDCD

Q24624398-274260E8-52A2-48CA-A403-3AF2533A8D67

Q24624398-2EA09D52-4A49-4561-8F18-2BADA9226C24

Q24624398-3350826B-0638-4C08-B361-FF03D4030BFE

Q24624398-43E2FAFD-37DE-41BC-B91E-1CE8A695147B

Q24624398-440FFFAB-E125-46F4-8B6F-A7FA5949555C

P304

Q24624398-8F725127-8909-478D-8CC0-E56322ED7DD2

P31

Q24624398-DC6F3E7F-F431-483C-A13C-AAD597010458

P356

Q24624398-69C0DB31-1350-4602-964C-6F2329B2B03D

P407

Q24624398-DCB3E362-B53B-41F9-A28C-E11FEC89AACB

P433

Q24624398-540B4D78-35F2-40C0-BB8D-70CDBDCC0F61

P478

Q24624398-A4F97F7A-74FB-4BCF-A64E-D13E6A42D78F

P50

Q24624398-2367FFF0-FC3B-4C45-8FA4-9BE15593FC4E

Q24624398-F570DAF2-37F8-4486-9532-93B97C9BE36D

P577

Q24624398-B67F4E35-B6E3-4145-9F05-45594B8B5B78

P5875

Q24624398-1E34746B-A2D4-4794-81C4-C5F728DA39FE

P698

Q24624398-0433046B-D723-4E56-A10F-544A920C61A9

P921

Q24624398-0E149EA1-EFBF-4B4E-8100-52AB23FB432C

P932

Q24624398-4AAE1907-DEEF-44B9-8387-D087C8DA4F9E

P356

BLOOD-2008-02-138602

P1433

P1476

Appraisal of immunoglobulin free light chain as a marker of response

@en

P2093

Arthur R Bradwell

http://www.w3.org/2001/XMLSchema#string

Emily Blood

http://www.w3.org/2001/XMLSchema#string

Jerry A Katzmann

http://www.w3.org/2001/XMLSchema#string

Kimberly Henderson

http://www.w3.org/2001/XMLSchema#string

Lijun Zhang

http://www.w3.org/2001/XMLSchema#string

Martin M Oken

http://www.w3.org/2001/XMLSchema#string

Melissa Snyder

http://www.w3.org/2001/XMLSchema#string

Philip R Greipp

http://www.w3.org/2001/XMLSchema#string

Roberta Degoey

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Immunoglobulin free light chains and solitary plasmacytoma of bone

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma.

Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.

Serum test for assessment of patients with Bence Jones myeloma.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

P304

4908-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-02-138602

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

P577

2008-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5488926

http://www.w3.org/2001/XMLSchema#string

P698

18364469

http://www.w3.org/2001/XMLSchema#string

P921

P932

2964259

http://www.w3.org/2001/XMLSchema#string